Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings.
Vol 23, No 16S (June 1 Supplement), 2005: 1582
© 2005 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sridhar, P. S. Articles by Rath, G. K. Search for Related Content PubMed Articles by Sridhar, P. S. Articles by Rath, G. K.

Abstract

Gliosarcoma - clinical study

All India Institute Medcl Sciences (AIIMS), New Delhi, India

1582

Background: Gliosarcomas are rare neoplasm of central nervous system. Consisting gliomatous and sarcomatous components. No clear data is available regarding its cell of origin and behavior. This study examines clinical features, treatment and survival. Methods: 14 patients of Gliosarcomas treated between Jan 1993 to June 2004 were analyzed retrospectively.10 were male, 4 female, with median age of 50 years (range 12–70 yrs). All were situated in supratentorium, 8 were left side, 6 right side.7 in temporal region, 4 in temporoparietal and 3 in parietal region. All patients underwent surgery and 12 patients received postoperative radiotherapy to dose of 60 Gy/30 fractions in 6 weeks.10 patients received platinum based chemotherapy.2 patient received concurrent taxane and radiotherapy. Results: Median survival was 9.3 months, 10 patients died of disease, 2 patients stable disease, and 1 patient is in PR and 1 in CR. Conclusions: Gliosarcoma is aggressive neoplasm; Clinically indistinguishable from GBM.Chemoradiotherapy is beneficial

No significant financial relationships to disclose.